C

Climb Bio Inc
D

CLYM

10.545
USD
-0.44
(-3.96%)
مغلق
حجم التداول
46,526
الربح لكل سهم
-1
العائد الربحي
-
P/E
-14
حجم السوق
603,838,578
المقالات
المزيد

العنوان: Climb Bio Inc

القطاع: Healthcare
الصناعة: Biotechnology
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.